Cover Image
市場調查報告書

吸入型慢性阻塞性肺病治療藥市場

Inhaled COPD Therapeutics

出版商 Greystone Research Associates 商品編碼 304992
出版日期 內容資訊 英文
商品交期: 最快1-2個工作天內
價格
Back to Top
吸入型慢性阻塞性肺病治療藥市場 Inhaled COPD Therapeutics
出版日期: 2014年06月04日 內容資訊: 英文
簡介

慢性阻塞性肺病(COPD)非單一而是集合複數症狀,各種症狀存在獨自的病因和治療課題。慢性支氣管炎是指支氣管內壁的發炎和導致的疤痕。慢性阻塞性肺病口腔吸入劑,幾乎半數是組合了2種藥物的產品,反映了嘗試應對慢性阻塞性肺病相關獨自且困難的治療因素的設計因素。因此產生的設備容易使用,內建安全功能,並且也對應著並進遵守的提高。

本報告提供吸入型慢性阻塞性肺病治療藥市場相關研究、慢性阻塞性肺病治療藥市場動態、慢性阻塞性肺病技術概要及產品開發趨勢、慢性阻塞性肺病吸入器設計要素彙整、吸入型慢性阻塞性肺病產品的市場預測、法規及基準環境、管理護理及醫療費付款者倡議的現狀彙整、主要企業簡介等,為您概述為以下內容。

摘要整理

慢性阻塞性肺病治療藥市場動態

  • 設備、處方、市場發展
  • 確立的治療目標
    • 競爭的投藥形態
  • 處方趨勢
    • 治療策略
  • 促進成長的因素

慢性阻塞性肺病技術與產品開發因素

  • 藥品處方和處方技術
    • 吸入設備設計要素
  • 乾燥粉末吸入器
  • 定量吸入器
  • 噴霧器
    • 投藥重現性
  • 活性化合物的穩定性
    • 新的設備技術

慢性阻塞性肺病吸入器設計要素

  • 新的處方技術
    • 便於病人使用的給藥/指導技術
    • 用戶確認/回饋/疾病管理
  • 組合(多藥)吸入器

慢性阻塞性肺病吸入產品分析、市場資料、預測

  • 抗膽鹼促效劑
    • 抗膽鹼促效劑/SABA
  • 抗膽鹼促效劑/LABA
    • ICS/SABA
  • LABA
  • 其他重要/新興藥品等級

市場要素

  • 法規及標準
  • 臨床試驗
  • 醫療經濟
  • 管理護理與醫療費付款者倡議

企業簡介

目錄
Product Code: CPD259K

COPD is not one but a family of conditions, each with its own etiology and treatment challenges. Chronic bronchitis is the inflammation and eventual scarring of the lining of the bronchial tubes. Oral COPD inhalers, half of which are two-drug combination products, include design elements that attempt to address the unique and challenging treatment factors associated with COPD. The resulting devices are user-friendly and incorporate designed-in safety features, and in the process support the parallel goal of improved compliance. While not curative, these inhalable drug products provide patients with symptomatic relief while reducing the morbidity associated with this progressive disease.

Highlights

  • Analyzes therapeutic drugs and pipeline candidates delivered via oral inhalers for treating COPD
  • Assesses inhalation device technology for commercial and development-stage devices, and evaluates product technology issues and evolving market factors
  • Provides detailed assessments of inhaled drug targeted disease segments, growth prospects and market potential
  • Provides market data and forecasts for inhaled COPD therapeutic drugs to 2020
  • Profiles inhaled drug product market participants, their technology, product development activity, and business strategies
  • Evaluates the impact of economic, technology, and regulatory factors on inhaled drug companies and their alliance partners

Table of Contents

Executive Summary

COPD Therapeutics Market Dynamics

  • Devices, Formulations and Market Evolution
  • Established Therapeutic Targets
    • Competing Dosage Forms
  • Prescribing Trends
    • Therapeutic Strategies
  • Factors Driving Growth

COPD Technology & Product Development Factors

  • Drug Formulations & Formulation Technologies
    • Inhalation Device Design Factors
  • Dry Powder Inhalers
  • Metered Dose Inhalers
  • Nebulizers
    • Dose Reproducibility
  • Active Compound Stability
    • Emerging Device Technologies

COPD Inhaler Design Factors

  • Novel Formulation Technology
    • Patient-friendly Administration/Coaching Technology
    • User Confirmation/Feedback/Disease Management
    • Embedded Electronics
  • Combination (multidrug) Inhalers

Inhaled COPD Product Analysis, Market Data & Forecasts

  • Anticholinergics
    • Anticholinergic/SABA
  • Antocholinergic/LABA
    • ICS/LABA
  • LABA
  • Other Important/Emerging Drug Classes

Market Factors

  • Regulations and Standards
  • Clinical Trials
  • Healthcare Economics
  • Managed Care and Payor Initiatives

Company Profiles

Back to Top